Ulcerative colitis Market: Epidemiology, Therapies, Companies, DelveInsight | Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesobl

Ulcerative colitis therapies, such as SIMPONI (golimumab), ENTYVIO (vedolizumab), Etrasimod (APD334), ABX464 (obefazimod), SHR0302 (Ivarmacitinib), and others, are expected to boost the Ulcerative colitis Market in the upcoming years.

DelveInsight has launched a new report on "Ulcerative colitis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Ulcerative colitis, historical and forecasted epidemiology as well as the Ulcerative colitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Ulcerative colitis market report @ https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Ulcerative colitis Market Report:

In 2023, the ulcerative colitis market across the seven major markets (7MM) was valued at approximately USD 8.4 billion. The market is expected to experience growth driven by increased adoption of current therapies and heightened disease awareness.
Managing ulcerative colitis is multifaceted, typically involving medications, dietary and nutritional changes, and, in some cases, surgical intervention to address damaged areas of the gastrointestinal tract.
A range of drug classes are currently used for treatment, including aminosalicylates, corticosteroids, immunomodulators, biologics, S1P modulators, Janus kinase (JAK) inhibitors, among others. Nonetheless, the treatment landscape is undergoing change as new therapies are developed.
Despite the available options, the effectiveness of existing treatments is limited for some patients, often leading to treatment discontinuation and a need for novel therapeutic approaches.
In the U.S., several medications are approved for moderate to severe cases, such as anti-TNFα agents (adalimumab, infliximab, golimumab), interleukin inhibitors (ustekinumab, mirikizumab), anti-integrin therapies (vedolizumab), S1P modulators (ozanimod), and JAK inhibitors (tofacitinib, upadacitinib).
The U.S. held the largest share of the ulcerative colitis market in 2023, with an estimated value of USD 5.9 billion, and this figure is projected to rise by 2034.
Emerging treatments like obefazimod (Abivax), risankizumab (AbbVie/Boehringer Ingelheim), and guselkumab (Janssen) are expected to further diversify and enhance the treatment landscape.
DelveInsight estimates that in 2023, there were around 521,000 diagnosed cases of mild ulcerative colitis and approximately 860,000 moderate to severe cases across the EU4 countries and the UK. These numbers are expected to rise over the forecast period.
In March 2025, Celltrion launched STEQEYMA® (ustekinumab-stba) in the U.S., a biosimilar to STELARA® (ustekinumab), following its FDA approval in December 2024. STEQEYMA has been cleared for all the same indications as STELARA, ensuring continuity in treatment options for both patients and healthcare providers.
In January 2025, Rise Therapeutics announced that the FDA had accepted its Investigational New Drug (IND) application to initiate a Phase 1 oncology trial for R-5780. This represents the company's fourth clinical program, with ongoing development efforts also targeting ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.
In December 2024, Biocon Biologics Ltd (a Biocon Ltd subsidiary) received FDA approval for YESINTEKTM (ustekinumab-kfce), a biosimilar of Stelara®. YESINTEKTM, a monoclonal antibody, has been approved for use in treating Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Key Ulcerative colitis companies such as Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, and others are evaluating new drugs for Ulcerative colitis to improve the treatment landscape.
Promising Ulcerative colitis therapies include SIMPONI (golimumab), ENTYVIO (vedolizumab), Etrasimod (APD334), ABX464 (obefazimod), SHR0302 (Ivarmacitinib), and others.

Ulcerative colitis Overview

Ulcerative colitis is one of the two primary types of chronic inflammatory bowel disease (IBD), the other being Crohn's disease. It is a long-term, idiopathic inflammatory condition affecting the lining of the colon and is typically marked by symptoms such as diarrhea, abdominal pain, and rectal bleeding.

There is no single definitive test for diagnosing ulcerative colitis. Instead, diagnosis relies on a combination of clinical symptoms and various diagnostic tools including endoscopy, biopsy, stool analysis, and imaging techniques like X-rays, fluoroscopy, CT scans, and MRIs. Additional lab tests, such as complete blood count, inflammatory markers, liver function, and electrolyte levels, are also commonly used.

Flexible sigmoidoscopy and colonoscopy are considered the most reliable methods for confirming ulcerative colitis and distinguishing it from other conditions like Crohn's disease, diverticulitis, or colorectal cancer. Blood tests that detect specific antibodies can also assist in differential diagnosis; for example, many ulcerative colitis patients test positive for perinuclear anti-neutrophil antibodies (pANCA), while Crohn's disease patients more often have anti-Saccharomyces cerevisiae antibodies (ASCA).

Ulcerative colitis market forecast reports typically offer insights into the disease's pathophysiology, diagnostic strategies, and treatment protocols. They also outline the patient journey-from the onset of symptoms through diagnosis and ongoing management-providing a comprehensive view of real-world clinical practice.

Ulcerative colitis Market Outlook

Ulcerative colitis treatment involves a multifaceted approach that includes medications, dietary modifications, and, when necessary, surgical intervention to address affected areas of the gastrointestinal tract. The current treatment landscape includes established therapies like aminosalicylates, corticosteroids, thiopurines, calcineurin inhibitors, and biologics such as anti-TNF agents (e.g., adalimumab, infliximab, golimumab), anti-adhesion molecules (vedolizumab), JAK inhibitors (tofacitinib), IL-12/23 inhibitors (ustekinumab), and S1P modulators (ozanimod).

U.S. guidelines recommend aminosalicylates or corticosteroid induction followed by aminosalicylate maintenance for mild-to-moderate cases. For moderate-to-severe disease, immunosuppressants like azathioprine or biologics such as infliximab or adalimumab-alone or combined with immunosuppressants-are often used to induce and maintain remission.

Across the 7 major markets (7MM), treatment choices vary slightly, but the market is generally segmented by commonly used drug classes, including conventional therapies, biologics, and targeted small molecules.

Looking ahead, the introduction of new therapies, improved early screening, expanded treatment access, and heightened awareness are expected to enhance management outcomes. However, the high cost of innovative treatments and complications may limit widespread adoption.

Several companies, including Abivax, AbbVie/Boehringer Ingelheim, and Janssen, are advancing pipeline drugs like obefazimod, risankizumab, and guselkumab, aiming to expand therapeutic options for ulcerative colitis.

Discover how the Ulcerative colitis market is rising in the coming years @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Ulcerative Colitis Marketed Drugs
SIMPONI (golimumab): Janssen Pharmaceuticals
ENTYVIO (vedolizumab): Takeda Pharmaceuticals
Etrasimod (APD334): Arena Pharmaceuticals/Pfizer

Ulcerative colitis Emerging Drugs
ABX464 (obefazimod): Abivax
SHR0302 (Ivarmacitinib): Reistone Biopharma

Scope of the Ulcerative colitis Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Ulcerative colitis Companies: Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, and others
Key Ulcerative colitis Therapies: SIMPONI (golimumab), ENTYVIO (vedolizumab), Etrasimod (APD334), ABX464 (obefazimod), SHR0302 (Ivarmacitinib), and others
Ulcerative colitis Therapeutic Assessment: Ulcerative colitis current marketed and Ulcerative colitis emerging therapies
Ulcerative colitis Market Dynamics: Ulcerative colitis market drivers and Ulcerative colitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Ulcerative colitis Unmet Needs, KOL's views, Analyst's views, Ulcerative colitis Market Access and Reimbursement

To know what's more in our Ulcerative colitis report, visit https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Ulcerative colitis Market Report:
Ulcerative colitis market report covers a descriptive overview and comprehensive insight of the Ulcerative colitis Epidemiology and Ulcerative colitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Ulcerative colitis market report provides insights into the current and emerging therapies.
The Ulcerative colitis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Ulcerative colitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Ulcerative colitis market.

Got queries? Click here to know more about the Ulcerative colitis market Landscape https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Ulcerative colitis Patient Share (%) Overview at a Glance
5. Ulcerative colitis Market Overview at a Glance
6. Ulcerative colitis Disease Background and Overview
7. Ulcerative colitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Ulcerative colitis
9. Ulcerative colitis Current Treatment and Medical Practices
10. Unmet Needs
11. Ulcerative colitis Emerging Therapies
12. Ulcerative colitis Market Outlook
13. Country-Wise Ulcerative colitis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Ulcerative colitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Ulcerative colitis Market Outlook 2034 https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Ulcerative colitis Pipeline Insights, DelveInsight

"Ulcerative colitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Ulcerative colitis market. A detailed picture of the Ulcerative colitis pipeline landscape is provided, which includes the disease overview and Ulcerative colitis treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.